Hayes, Inc. White Paper Explains the Gene Patenting Controversy Before the U.S. Supreme Court

Share Article

Ruling could impact access to genetic testing for women with breast cancer

Hayes, Inc. http://www.hayesinc.com , a leader in promoting better health outcomes through the use of evidence, has released its latest white paper, Gene Patenting in the United States—Where Have We Been, Where Are We Going? Complimentary copies of this publication are available here.

“For more than 30 years, the U.S. Patent and Trademark Office has issued patents on human genetic sequences, despite the objections of many in the genetics community that genes are products of nature rather than inventions,” explains Dr. Diane Allingham-Hawkins, PhD, FCCMG, FACMG, Senior Director, Genetic Test Evaluation Program and Technical Editing at Hayes, Inc. “After Myriad Genetics, which holds patents on genes associated with increased risk of breast and ovarian cancer, exercised its monopoly rights and prevented testing for these genes from being performed at laboratories other than its own, scientists and doctors around the world challenged its patents. The debate has reached a fever pitch with the U.S. Supreme Court set to hear opening arguments in the case on April 15, 2013. Regardless of the outcome, the Myriad Genetics case is sure to have a far-reaching impact on the availability and quality of genetic and genomic testing in the United States and around the world.”

Download this latest release from Hayes, Inc. to learn about the history of gene patenting in the United States, the ongoing patent challenge against Myriad Genetics, the approaches used in other countries, and how the Myriad patent challenge could affect the use of genetic testing around the world.

Hayes, Inc., an internationally recognized leader in health technology research and consulting, is dedicated to the delivery of high-quality healthcare and improved outcomes through the integration of evidence into decision making and policy development. The unbiased information and comparative-effectiveness analyses we provide enable evidence-based decisions about acquiring, managing, and paying for health technologies. Our worldwide clients include hospitals, healthcare systems, government agencies, health plans, and employers.

For more information about Hayes, Inc., visit http://www.hayesinc.com. Or, contact Hayes, Inc. by mail at 157 S. Broad Street, Lansdale, PA 19446; by telephone at 215.855.0615; by e-mail at hayesinfo(at)hayesinc(dot)com; or by fax at 215.855.5218.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Matthias
Visit website